Axsome Therapeutics Inc.
Axsome Therapeutics Enters $570M Loan and Credit Facility with Blackstone
Summary
Axsome Therapeutics, Inc. has entered into a $570 million term loan and revolving credit facility with Blackstone, consisting of a $500 million term loan and a $70 million revolving credit facility. The proceeds were used to repay its existing term loan with Hercules Capital. Concurrently, Blackstone purchased $15 million of Axsome's common stock. The new facility is expected to reduce interest expense and accelerate time to profitability.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement